Scarica l'app Stockscreener
1.27
3.79%
-0.05
Pre-mercato:
1.26
-0.01
-0.79%
Telomir Pharmaceuticals Inc Borsa (TELO) Ultime notizie
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer - ACCESS Newswire
Telomir Pharmaceuticals submits IND in U.S. for Telomir-1 in TNBC - BioWorld MedTech
Telomir submits IND application for cancer drug candidate By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Regains Nasdaq Listing Rule Compliance - TipRanks
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) Targeting Advanced Triple-Negative Breast Cancer - Minichart
Telomir Pharmaceuticals Regains Nasdaq Compliance Following 2025 Annual Shareholders Meeting - Minichart
Telomir Pharmaceuticals Submits IND for Telomir-1 in Advanced Triple-Negative Breast Cancer - National Today
Telomir Pharmaceuticals regains Nasdaq compliance after annual meeting - Investing.com
Nasdaq confirms Telomir (NASDAQ: TELO) back in listing compliance - stocktitan.net
Telomir submits IND application for cancer drug candidate - Investing.com
Telomir takes experimental TNBC therapy to FDA for metastatic disease - stocktitan.net
Telomir Pharmaceuticals submits IND application to FDA for Telomir-1 in TNBC - Investing.com
Telomir submits IND for Telomir-1 to treat advanced and metastatic TNBC - TradingView
Telomir Pharmaceuticals (NASDAQ: TELO) files IND for Telomir-1 in advanced TNBC - stocktitan.net
Telomir Shareholders Approve Equity Plan and Bylaw Changes - The Globe and Mail
Pullback Watch: Is Telomir Pharmaceuticals Inc stock a buy or sell2026 Weekly Recap & Technical Confirmation Trade Alerts - baoquankhu1.vn
Telomir Pharmaceuticals 2026 Annual Meeting Results: Shareholder Votes, Amended Bylaws, and Incentive Plan Approval - Minichart
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - Bluffton Today
Telomir Pharmaceuticals, Inc. unveils Telomir-1 for cellular dysfunction targeting iron and zinc balance - Traders Union
Telomir Pharmaceuticals shareholders approve acquisition and bylaw changes - Investing.com UK
Telomir Pharmaceuticals (NASDAQ: TELO) clears Teli deal and expands equity incentive plan - stocktitan.net
Pharma News: Should I trade or invest in Telomir Pharmaceuticals Inc2026 Earnings & AI Enhanced Trading Alerts - baoquankhu1.vn
Setup Watch: Is Telomir Pharmaceuticals Inc a cyclical or defensive stockMarket Trend Summary & Community Trade Idea Sharing Platform - baoquankhu1.vn
CEO Moves: Is Telomir Pharmaceuticals Inc stock good for income investors2026 Stock Rankings & Risk Managed Investment Signals - baoquankhu1.vn
Telomir Pharmaceuticals, Inc.: Preclinical Pipeline Targeting Aging and Age-Related Diseases with Novel Small-Molecule Therapeutics - Minichart
Insider Buy: How does Telomir Pharmaceuticals Inc score in quality rankingsMarket Rally & Real-Time Volume Triggers - baoquankhu1.vn
Telomir Pharmaceuticals 2025 10-K: $0 Revenue, $(0.33) EPS on $(10.41)M Net Loss - TradingView
Telomir Pharmaceuticals (NASDAQ: TELO) details 2025 results, Telomir-1 plans and TELI merger - Stock Titan
US Market Recap: Will Unisys Corporation stock go up in YEAR2026 Short Interest & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Telomir Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Winners Losers: Is Telomir Pharmaceuticals Inc a top pick in the sectorTrade Risk Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Risk Analysis: Can Genco Shipping Trading Limited be recession proofWall Street Watch & Daily Stock Momentum Reports - baoquankhu1.vn
Trading Action: Is Telomir Pharmaceuticals Inc. a good ESG investmentQuarterly Growth Report & Short-Term High Return Ideas - baoquankhu1.vn
Portfolio Recap: Will Telomir Pharmaceuticals Inc outperform small cap indexesJuly 2025 Update & Entry Point Confirmation Signals - baoquankhu1.vn
Nasdaq Moves: Is Telomir Pharmaceuticals Inc a good ESG investment2025 Momentum Check & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
TELO Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models - ACCESS Newswire
TELO Technical Analysis & ETF Price Forecast - Intellectia AI
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Activity Recap: Is Telomir Pharmaceuticals Inc stock influenced by commodity pricesCPI Data & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Valuation Update: What are the risks of holding Telomir Pharmaceuticals IncJuly 2025 Selloffs & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Telomir Pharmaceuticals Faces Crucial Corporate and Regulatory Deadlines () - aktiencheck.de
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Rating Upgraded by Wall Street Zen - Defense World
Is Telomir Pharmaceuticals Inc. stock a good dividend stockJuly 2025 Gainers & Verified Chart Pattern Signals - mfd.ru
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 4.2% – Should You Sell? - Defense World
Telomir Sets Vote on Transformative TELI Merger and Governance Changes - The Globe and Mail
Telomir reveals promising preclinical data for Telomir-Zn - TipRanks
Telomir Pharmaceuticals demonstrates broad tumor cell mortality in human triple-negative breast cancer models - marketscreener.com
Telomir Pharmaceuticals Inc's latest research shows that the company has achieved extensive tumor cell death rates in human triple-negative breast cancer experimental models. - Bitget
Telomir Pharmaceuticals, Inc. Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models - marketscreener.com
Telomir (NASDAQ: TELO) posts new Telomir-1 preclinical data in triple-negative breast cancer - Stock Titan
Experimental breast cancer drug triggers iron-dependent tumor cell death - Stock Titan
Investment Report: What are the risks of holding Telomir Pharmaceuticals IncJuly 2025 Technicals & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):